A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2002
11/07/2002	WO2002087496A2 Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling
11/07/2002	WO2002087472A1 Stent-based delivery of statins to prevent restenosis
11/07/2002	WO2002087465A2 Compositions and methods of double-targeting virus infections and cancer cells
11/07/2002	WO2002087335A1 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
11/07/2002	WO2002072635A3 Specific binding members
11/07/2002	WO2002068614A3 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
11/07/2002	WO2002067955A3 A process for the manufacture of a herbal composition comprising a matrine
11/07/2002	WO2002064546A3 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
11/07/2002	WO2002058775A3 Device for dilating and irradiating a vascular segment or body passageway
11/07/2002	WO2002056872A3 Antiproliferative colchicine compositions and uses thereof
11/07/2002	WO2002056708A3 Preparation for improved dietary utilisation
11/07/2002	WO2002047697A3 Fractions of snake blood, their preparation and use as therapeutic agents
11/07/2002	WO2002040001A3 Compositions for treatment of malignant effusions comprising a biocompatible polymer and antineoplastic taxane
11/07/2002	WO2002028424A3 Kyberdrug as autovaccines with immune-regulating effects
11/07/2002	WO2002026823A3 A novel human g-protein coupled receptor, hgprbmy7, expressed highly in spinal cord
11/07/2002	WO2002009768A3 Therapeutic polyesters and polyamides
11/07/2002	WO2002009667A3 Dispersions for formulating slightly or poorly soluble active ingredients
11/07/2002	WO2001085687A1 Substituted indoles as parp inhibitors
11/07/2002	WO2001048187A9 A molecular switch for regulating mammalian gene expression
11/07/2002	WO2001037859A3 Pharmaceutical compositions containing compounds which increase or decrease tmtnf levels
11/07/2002	WO2001027305A9 Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms
11/07/2002	WO2001027079A9 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
11/07/2002	WO2001026676A9 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
11/07/2002	WO2001015745A9 Method and formula for tumor remission and suppression of cancer
11/07/2002	WO2000064420A3 Compositions and methods for treating amyloidosis using sulphonate derivatives
11/07/2002	US20020166132 System for regulating in vivo the expression of a transgene by conditional inhibition
11/07/2002	US20020165412 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
11/07/2002	US20020165406 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
11/07/2002	US20020165394 Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
11/07/2002	US20020165378 Human membrane antigen tm4 superfamily protein and dna encoding this protein
11/07/2002	US20020165377 ADAM polynucleotides, polypeptides, and antibodies
11/07/2002	US20020165374 Secreted protein HFEAF41
11/07/2002	US20020165361 Antibody for use in the diagnosis and treatment of cell proliferation disorders
11/07/2002	US20020165355 Methylated, SmD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
11/07/2002	US20020165351 Novel compounds
11/07/2002	US20020165347 Polypeptide for use in the diagnosis, prevention and treatment of arteriosclerosis and vascular restenosis
11/07/2002	US20020165343 Growth hormone secretagogues
11/07/2002	US20020165275 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/07/2002	US20020165268 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
11/07/2002	US20020165258 For tumors that have initially been unresponsive to taxane therapy and developed drug resistance
11/07/2002	US20020165257 For patients exhibiting resistance to oncology and chemotherapy with taxanes; antiproliferative agents
11/07/2002	US20020165256 Fermentative preparation process for and crystal forms of cytostatics
11/07/2002	US20020165240 Method of treating proliferative diseases using Eg5 inhibitors
11/07/2002	US20020165229 Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
11/07/2002	US20020165223 Eating disorders; anticholesterol agents; hypotensive agents; sleep disorders
11/07/2002	US20020165218 Mixture of kinase inhibitor and anticancer agents
11/07/2002	US20020165203 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents
11/07/2002	US20020165201 Cyanoguanidine prodrugs
11/07/2002	US20020165193 Compositions and methods of treating tumors
11/07/2002	US20020165191 Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat
11/07/2002	US20020165190 Expression vector coding p972 gene for cancer therapy and adenovirus producing the same
11/07/2002	US20020165179 Multifunctional nanodevice platform
11/07/2002	US20020165173 T-cell factor (TCF); constructs having multiple repeats of a TCF-binding element linked to a promoter and used to express genes encoding therapeutic proteins; drug screening for anticancer agents that suppress transcription
11/07/2002	US20020165164 New effectors of dipeptidyl peptidase IV for topical use
11/07/2002	US20020165154 Lipoprotein-regulating medicaments
11/07/2002	US20020165150 Amino acid sequence from certain regions of tissue growth factor-beta super family serine-threonine kinase receptors
11/07/2002	US20020165141 Methods for promoting dendritic cell proliferation or differentiation
11/07/2002	US20020165131 Histidine-rich glycoprotein
11/07/2002	US20020165123 CXCR4 agonist treatment of hemapoietic cells
11/07/2002	US20020164799 Expression vector coding proteins for use in the treatment of cancer
11/07/2002	US20020164769 Nucleotide sequencces coding polypeptide for use in the treatment of cell proliferative disorders
11/07/2002	US20020164734 Human pelota homolog
11/07/2002	US20020164719 Targeting pharmaceutical agents to injured tissues
11/07/2002	US20020164715 Nucleotide seqences coding polypeptides for use in the treatment and diagnosis of cancer
11/07/2002	US20020164714 Nucleotie sequences coding polypeptide for use in the treatment of reproductive disorders
11/07/2002	US20020164707 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of cancer, arthrits, pain, diabetes, migraine and inflammation, hypercalcemia, obesity, hypertension, and bone defects
11/07/2002	US20020164690 Receptor based antagonists and methods of making and using
11/07/2002	US20020164667 VEGFR-3 inhibitor materials and methods
11/07/2002	US20020164600 PD-L2 molecules: novel PD-1 ligands and uses therefor
11/07/2002	US20020164390 Compositions containing an active fraction isolated from tricholoma conglobatum and methods of use
11/07/2002	US20020164378 Use of bioactive fraction from cow urine distillate ('Go-mutra') as a bio-enhancer of anti-infective, anti-cancer agents and nutrients
11/07/2002	US20020164377 Mixture of retinoic acid and paclitaxel; polymeric carrier
11/07/2002	US20020164376 Microparticles and their use in cancer treatment
11/07/2002	US20020164359 Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
11/07/2002	US20020164358 Culturing human cancer cells; purification, recovering of antigens
11/07/2002	US20020164355 Test to detect antibodies; calibration
11/07/2002	US20020164352 Dietetics; anticholesterol agents; antidiabetic agents
11/07/2002	US20020164349 Induction apoptosis; west nile virus therapy
11/07/2002	US20020164346 Induce, moderate immunology response
11/07/2002	US20020164338 Combined approach to treatment of cancer with hCG vaccines
11/07/2002	US20020164334 Antibody-induced apoptosis
11/07/2002	US20020164331 Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
11/07/2002	US20020164312 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/07/2002	US20020164287 Azo compounds for type i phototherapy
11/07/2002	DE10120505A1 Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen Use of stimulated peripheral blood mononuclear cells for the treatment of cancer
11/07/2002	DE10109897A1 Fakultativ kationische Liposomen und Verwendung dieser Optional cationic liposomes and use of these
11/07/2002	CA2715570A1 Cripto blocking antibodies and uses thereof
11/07/2002	CA2594883A1 Pharmaceutically active uridine esters
11/07/2002	CA2483758A1 Individualization of therapy with antineoplastic agents
11/07/2002	CA2448607A1 Colloidal metal compositions and methods
11/07/2002	CA2447748A1 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/07/2002	CA2446064A1 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	CA2445967A1 Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
11/07/2002	CA2445861A1 Pharmaceutically active uridine esters
11/07/2002	CA2445702A1 Control of compactability through crystallization
11/07/2002	CA2445629A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
11/07/2002	CA2445593A1 Genetically modified yt cell line and use thereof
11/07/2002	CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	CA2445565A1 Compositions and methods of double-targeting virus infections and cancer cells
11/07/2002	CA2445524A1 Stent-based delivery of statins to prevent restenosis

1 ... 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 ... 2211